What is Mesenbio?
Mesenbio is a preclinical biopharmaceutical company originating from the University of York. The company's core innovation is its Cell Line Extracellular Vesicle Release (CLEVR) platform, designed to overcome the critical challenge of consistency in extracellular vesicle production. By ensuring a reliable and scalable supply of EVs, Mesenbio aims to unlock their potential as a novel therapeutic modality and transform the treatment landscape for various diseases.
How much funding has Mesenbio raised?
Mesenbio has raised a total of $1.8M across 1 funding round:
Other Financing Round
$1.8M
Other Financing Round (2024): $1.8M with participation from NG Bio
Key Investors in Mesenbio
NG Bio
NG Bio Ltd is focused on developing breakthrough cures for chronic diseases, operating under the advisory of Midmar Capital LLP. They target individuals and organizations seeking innovative healthcare solutions and are committed to advancing medical research.
What's next for Mesenbio?
With this significant enterprise-level backing, Mesenbio is poised to advance its therapeutic pipeline. The focus will likely be on further validating the CLEVR platform, progressing its lead candidates through preclinical development, and potentially initiating early-stage clinical trials. Strategic partnerships and continued investment will be crucial for scaling operations and bringing these novel EV-based therapies to market, addressing unmet medical needs.
See full Mesenbio company page
